Experimental in vitro and in vivo studies have indicated that TGBR3 have antitumoral effects in CCRCC cells independent of TGF-β1 and canonical TGFBR1/TGFBR2/SMAD signaling [11]. The gene discussed is TGFBR2; the disease is nonpapillary renal cell carcinoma.